gip and glp-1 receptor agonist The dual glucose-dependent insulinotropic polypeptide (GIP) glucagon-like peptide-1 (GLP-1) tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology Possible mechanisms of action of

A look at lapsed users shows that three-fifths (61%) of individuals previously using GLP-1 drugs for weight loss discontinued within six months, with a third (33%) lapsing in three months or less

Though often covered by insurance, newer GLP-1 medications are often much more expensive than other glucose-lowering medications like sulfonylureas, metformin, and thiazolidinediones

Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: post hoc analyses from DECLARE-TIMI 58

Tirzepatide, marketed as Zepbound for weight management, has shown higher average weight loss than semaglutide in many trial comparisons

The SUMMIT trial demonstrated that tirzepatide significantly reduced the risk of HF hospitalisation or an urgent visit requiring intravenous diuretics

all patients should titrate to 1.2 mg after the first week to receive therapeutic levels for maximum antiglycemic effect (14)